Skip to main content

Table 2 Characteristics of patients with Pseudomonas aeruginosa ventilator-associated pneumonia at admission to the intensive care unit

From: Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa

Characteristics

PSPA-VAP N = 153

PRPA-VAP N = 70

P a

Male sex

119 (78)

55 (79)

0.75

Age

68 (55 to 76)

66 (49 to 77)

0.54

Type of admission

Medical

106 (69)

46 (66)

0.83

 

Surgical

27 (18)

15 (21)

0.53

 

Scheduled

20 (13)

9 (13)

0.65

SAPS II

 

48 (38 to 61)

48 (38 to 55)

0.80

Main diagnosis at admission

Septic shock

23 (15)

20 (29)

0.02

 

Multiple organ failure

8 (5)

4 (6)

0.79

 

Cardiovascular failure

6 (4)

1 (1)

0.64

 

Respiratory failure

55 (36)

19 (27)

0.14

 

Acute respiratory exacerbation of chronic pulmonary diseases

9 (6)

5 (7)

0.61

 

Acute renal failure

4 (3)

1 (1)

0.57

 

Scheduled surgery

4 (3)

6 (9)

0.02

Treatments within 48 hrs of ICU admission

Vasopressors

101 (66)

42 (60)

0.25

 

Steroids

50 (33)

24 (34)

0.67

 

Broad-spectrum antimicrobials

92 (60)

54 (77)

0.03

Duration of ICU stay before VAP

9 (6 to 17)

11 (6 to 18)

0.23

Organ dysfunction scores the day before VAP

LOD

5 (3 to 7)

4.5 (3 to 7)

0.56

 

SOFA

6 (3 to 8)

5 (3 to 7)

0.77

Polymicrobial VAP

45 (29)

18 (26)

0.53

Positive blood culture

6 (4)

7 (10)

0.11

Duration of stay

ICU

29 (17 to 48)

28,5 (18 to 48)

0.37

 

Hospital

47.5 (28 to 72)

50 (28 to 68)

0.24

  1. Data are the number (%) of patients (minimum to maximum). ICU, intensive care unit; LOD, logistic organ dysfunction; PRPA, piperacillin resistant Pseudomonas aeruginosa; PSPA, piperacillin sensitive Pseudomonas aeruginosa; SAPS II, Simplified Acute Physiology Score version II; SOFA, Simplified Organ Failure Assessment; VAP, ventilator-associated pneumonia.
  2. a Wald χ2 test in conditional regression